246 related articles for article (PubMed ID: 24716923)
21. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
23. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer.
Andrade JM; Carrara HH; Pimentel FF; Marana HR; Macchetti AH; Mouro LR; Zola FE; Tiezzi DG
Med Oncol; 2011 Dec; 28 Suppl 1():S65-9. PubMed ID: 20953738
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer.
Won HS; Kim YS; Kim JS; Chang ED; Na SJ; Whang IY; Lee DS
Korean J Intern Med; 2020 Nov; 35(6):1489-1496. PubMed ID: 32069523
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
[TBL] [Abstract][Full Text] [Related]
26. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
27. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
28. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L
Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Gu X; Jia S; Wei W; Zhang WH
Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
[TBL] [Abstract][Full Text] [Related]
30. Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study.
Lombardi D; Scalone S; Crivellari D; Magri MD; La Mura N; Miolo G; Murrone A; Perin T; Coran F; Candiani E; Massarut S; Veronesi A
Tumori; 2010; 96(2):229-33. PubMed ID: 20572578
[TBL] [Abstract][Full Text] [Related]
31. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Bonnefoi H; Piccart M; Bogaerts J; Mauriac L; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Blot E; Zaman K; Cufer T; Lortholary A; Lidbrink E; André S; Litière S; Lago LD; Becette V; Cameron DA; Bergh J; Iggo R;
Lancet Oncol; 2011 Jun; 12(6):527-39. PubMed ID: 21570352
[TBL] [Abstract][Full Text] [Related]
32. Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer.
Hirano A; Shimizu T; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Aiba M; Ogawa K
Anticancer Res; 2008; 28(6B):4137-42. PubMed ID: 19192673
[TBL] [Abstract][Full Text] [Related]
33. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
[TBL] [Abstract][Full Text] [Related]
34. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
[TBL] [Abstract][Full Text] [Related]
35. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Kountourakis P; Missitzis I; Doufexis D; Zobolas V; Pissakas G; Arnogiannaki N; Maliou S; Sotiropoulou A; Ardavanis A
J Cancer Res Clin Oncol; 2011 Feb; 137(2):221-8. PubMed ID: 20387073
[TBL] [Abstract][Full Text] [Related]
37. Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.
Matthews CM; Nymberg K; Berger M; Vargo CA; Dempsey J; Li J; Ramaswamy B; Reinbolt R; Sardesai S; Wesolowski R; Williams N; Lustberg M
J Oncol Pharm Pract; 2020 Apr; 26(3):572-579. PubMed ID: 31256745
[TBL] [Abstract][Full Text] [Related]
38. Correlation of Preoperative Ki67 and Serum CA15.3 Levels with Outcome in Early Breast Cancers a Multi Institutional Study.
Rasmy A; Abozeed W; Elsamany S; Baiomy ME; Nashwa A; Amrallah A; Hasaan E; Alzahrani A; Faris M; Alsaleh K; AlFaraj A
Asian Pac J Cancer Prev; 2016; 17(7):3595-600. PubMed ID: 27510014
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological profile of breast cancer: An institutional experience.
Gogia A; Deo SV; Shukla NK; Mathur S; Sharma DN; Tiwari A
Indian J Cancer; 2018; 55(3):210-213. PubMed ID: 30693880
[TBL] [Abstract][Full Text] [Related]
40. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]